NCT07205705

Brief Summary

There is limited research on the impact of millets on glycemia, and it remains unclear whether partially replacing wheat in rotis with low glycemic index millets or Bengal gram flour offers greater glycemic benefits compared to whole wheat. This approach has the potential to reduce postprandial and overall glycemia, supporting the reversal of prediabetes through dietary modification alone. This study introduces a novel formulation of rotis using 50:50 blends of wheat with either barnyard millet, barley, or Bengal gram flour, aiming to improve glycemic control without compromising taste. Glycemic response is assessed through a combination of meal tolerance tests, continuous glucose monitoring, and a three-month dietary intervention, providing both immediate and long-term data. Additionally, the study includes a comprehensive metabolic evaluation by measuring serum insulin, inflammatory markers, and free fatty acids key indicators in the progression of prediabetes. Conducted as a randomized controlled trial with 80 participants across four arms (20 per arm), the study comprises three phases: Phase I evaluates immediate glycemic response through a meal tolerance test; Phase II uses continuous glucose monitoring over three days to monitor fluctuations in glucose levels; and Phase III, with 140 participants, assesses the long-term impact of the dietary intervention over three months. The primary objectives are to determine the effect of the interventions on glycemic response and HbA1c, with an expected outcome of a 10% reduction in the area under the curve for overall and postprandial glucose in Phases I and II, and a 10% reduction in HbA1c in Phase III.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
140

participants targeted

Target at P50-P75 for not_applicable

Timeline
19mo left

Started Nov 2025

Typical duration for not_applicable

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress24%
Nov 2025Nov 2027

First Submitted

Initial submission to the registry

September 10, 2025

Completed
23 days until next milestone

First Posted

Study publicly available on registry

October 3, 2025

Completed
1 month until next milestone

Study Start

First participant enrolled

November 15, 2025

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 15, 2027

Expected
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 20, 2027

Last Updated

October 3, 2025

Status Verified

September 1, 2025

Enrollment Period

1.8 years

First QC Date

September 10, 2025

Last Update Submit

September 25, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • HbA1c (%)

    3 months

Secondary Outcomes (1)

  • fasting glucose mg/dL) and satiety

    3 months

Study Arms (2)

Control Group

NO INTERVENTION

Wheat

Intervention Group

EXPERIMENTAL

Wheat + Barnyard millet/ Wheat +Barley/ wheat+ Bengal gram flour

Dietary Supplement: Millet

Interventions

MilletDIETARY_SUPPLEMENT

Wheat + Barnyard millet/ Wheat +Barley/ wheat+ Bengal gram flour

Intervention Group

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Age 18 to 60 years
  • Prediabetes as diagnosed on oral glucose tolerance test (OGTT): Fasting blood glucose ≥100mg/dl and \<126 mg/dl and/or 2-h plasma glucose ≥140mg/dl and \<200mg/dl (after ingestion of 75 gram anhydrous oral glucose).

You may not qualify if:

  • Acute infections and advanced end-organ damage
  • History of hepatitis or pancreatitis, abnormal liver and renal functions
  • Recent (\<3 months) changes in weight (≥5%) and/or weight-changing medications
  • Any known allergy to wheat or any other grain
  • Subjects with uncontrolled hypothyroidism or hypertension
  • On any drug causing weight gain or weight loss

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Glucose Intolerance

Interventions

foxtail millet trypsin inhibitor III

Condition Hierarchy (Ancestors)

HyperglycemiaGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Central Study Contacts

Anoop Misra, M.D.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 10, 2025

First Posted

October 3, 2025

Study Start

November 15, 2025

Primary Completion (Estimated)

September 15, 2027

Study Completion (Estimated)

November 20, 2027

Last Updated

October 3, 2025

Record last verified: 2025-09

Data Sharing

IPD Sharing
Will not share